^
Association details:
| Biomarker: | CD123 positive |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | MGD024 (CD3 agonist, CD123 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia
Published date:
11/04/2021
Excerpt:
To explore whether MGD024 could complement AML standard of care (SOC), we investigated combination therapy in mouse models...MGD024 demonstrated reduced in vitro potency in killing CD123-positive target cells compared to flotetuzumab or RES234M1.1...Similarly, MGD024 showed reduced potency in vivo against CD123-positive tumors compared to RES234M1.1...
DOI:
10.1182/blood-2021-153192
